IDT Australia Limited (AU:IDT)
ASX:IDT
Want to see AU:IDT full AI Analyst Report?
Top Page
IDT Australia Limited
(Sydney:IDT)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.03
▼(-36.00% Downside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial performance—ongoing losses and negative operating/free cash flows create material profitability and liquidity risk. Technicals are also broadly bearish with the stock below major moving averages, though the very low RSI indicates oversold conditions. Valuation remains difficult to justify on earnings due to losses and no dividend yield data.
Positive Factors
Business model resilience (CDMO fee-for-service)
IDT's fee-for-service CDMO model sells manufacturing and development as contracted services rather than relying on single-product sales. That structure yields diversified, client-funded revenue streams, reduces product development risk, and supports predictable contract revenues and long-term customer relationships.
Negative Factors
Negative cash flow generation
Persistent negative operating and free cash flows reduce internal funding for working capital, maintenance and capacity investments. Over the medium term this elevates liquidity risk and increases reliance on external financing, which can constrain competitiveness and contract execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model resilience (CDMO fee-for-service)
IDT's fee-for-service CDMO model sells manufacturing and development as contracted services rather than relying on single-product sales. That structure yields diversified, client-funded revenue streams, reduces product development risk, and supports predictable contract revenues and long-term customer relationships.
Read all positive factors
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.57M
Dividend YieldN/A
Average Volume (3M)336.94K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth6.14%
EPS Growth-20.00%
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,425,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)1.73
Price to Sales (P/S)1.92
P/FCF Ratio-5.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDT Australia Limited Business Overview & Revenue Model
Company Description
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and ...
How the Company Makes Money
IDT makes money primarily by providing fee-for-service pharmaceutical manufacturing and related technical services to third-party customers. Key revenue streams include (1) contract manufacturing revenues from producing finished pharmaceutical pro...
IDT Australia Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.00M | 19.77M | 13.23M | 6.93M | 12.11M | 15.99M |
| Gross Profit | 7.10M | 9.69M | 10.42M | -3.53M | 2.82M | 4.88M |
| EBITDA | -4.11M | -6.54M | -5.56M | -8.83M | -340.00K | 2.75M |
| Net Income | -6.13M | -8.06M | -5.41M | -8.50M | -1.16M | 2.10M |
Balance Sheet | ||||||
| Total Assets | 34.55M | 36.92M | 31.37M | 28.29M | 30.08M | 34.13M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 4.11M | 904.00K | 4.43M | 9.21M | 6.93M |
| Total Debt | 9.86M | 10.40M | 4.47M | 740.00K | 881.00K | 766.00K |
| Total Liabilities | 14.23M | 15.03M | 7.93M | 4.15M | 3.46M | 6.51M |
| Stockholders Equity | 20.31M | 21.89M | 23.44M | 24.14M | 26.63M | 27.61M |
Cash Flow | ||||||
| Free Cash Flow | -885.00K | -7.55M | -10.30M | -8.42M | 1.95M | -156.00K |
| Operating Cash Flow | 609.00K | -6.25M | -9.60M | -7.90M | 2.86M | 370.00K |
| Investing Cash Flow | -3.19M | -4.50M | -1.09M | -522.00K | -912.00K | -526.00K |
| Financing Cash Flow | 3.46M | 10.75M | 6.77M | 3.64M | 337.00K | 224.00K |
IDT Australia Limited Technical Analysis
Negative
0.05
Price Trends
0.04
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
39.03
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.03 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.
IDT Australia Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$20.21M | 25.77 | 1.66% | 3.28% | 2.11% | -64.71% | |
55 Neutral | AU$42.25M | -98.19 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$66.42M | 2.83 | 10.34% | ― | 15.21% | -141.82% | |
42 Neutral | AU$13.57M | -2.24 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:IDT
IDT Australia Limited
0.03
-0.06
-62.22%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.02
-23.00%
AU:MVP
Medical Developments International Limited
0.42
-0.15
-27.19%
AU:VIT
Cronos Australia Ltd.
0.03
-0.03
-50.85%
IDT Australia Limited Corporate Events
IDT Australia Director Geoffrey Sam Increases Indirect Shareholding
May 6, 2026
IDT Australia Limited has reported a change in the interests of director Geoffrey Sam, who has increased his indirect holding in the company through family-related entities. The transactions, conducted via on-market trades on 30 April 2026 at pric...
IDT Australia tips sharp earnings improvement on Sanofi tie-up and US policy tailwinds
Apr 28, 2026
IDT Australia has reported that, despite a weak March quarter due to a scheduled maintenance shutdown and seasonal public holidays, it expects its best fourth-quarter performance since launching a transformation program more than two years ago. Th...
IDT Australia Director Increases Indirect Shareholding via On-Market Trades
Mar 26, 2026
IDT Australia director Mark Simari has increased his indirect shareholding in the company through entities Charkaroo Pty Ltd and Jodmar Pty Ltd, which collectively acquired 325,000 fully paid ordinary shares in on-market trades. The purchases, exe...
IDT Australia Tightens Governance with Revised Security Trading Policy
Mar 26, 2026
IDT Australia Limited has updated its Security Trading Policy in line with ASX Listing Rule 12.10, reflecting the company’s ongoing focus on regulatory compliance and governance standards in its role as a specialist contract pharmaceutical m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.